VYNE Therapeutics (VYNE) Cost of Revenue (2020 - 2021)

VYNE Therapeutics (VYNE) posted Cost of Revenue of $903000.0 for Q4 2021, down 13.92% on a QoQ basis from $1.0 million in Q3 2021, and up 69.1% year-over-year from $534000.0 in Q4 2020.

VYNE Therapeutics (VYNE) Cost of Revenue (2020 - 2021) Analysis & Trends

VYNE Therapeutics' Cost of Revenue history runs 2 years deep, the most recent figure standing at $903000.0 for Q4 2021.

  • Quarterly Cost of Revenue rose 69.1% year-over-year to $903000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.3 million (up 140.52% YoY) and the FY2021 annual result came in at $3.3 million, up 140.52% from the prior year.
  • Cost of Revenue was $903000.0 for Q4 2021 at VYNE Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.0 million in Q3 2021 and bottomed at $216000.0 in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 167.22 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 392.80 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 296.00 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 903,000.00
Dec 31, 2021 903,000.00
Sep 30, 2021 1.05 Mn
Sep 30, 2021 1.05 Mn
Jun 30, 2021 795,000.00
Jun 30, 2021 795,000.00
Mar 31, 2021 601,000.00
Mar 31, 2021 601,000.00
Dec 31, 2020 534,000.00
Dec 31, 2020 534,000.00
Sep 30, 2020 371,000.00
Sep 30, 2020 371,000.00
Jun 30, 2020 216,000.00
Jun 30, 2020 216,000.00
Mar 31, 2020 271,000.00
Mar 31, 2020 271,000.00